Cancer immunotherapy's most celebrated checkpoint inhibitor may be undermining its own effectiveness through an unrecognized mechanism that removes the very immune cells it aims to activate. This finding could explain why some patients with liver-related cancers or chronic infections respond poorly to PD-1 blockade therapy. The research reveals that standard PD-1 antibodies containing intact Fc regions trigger selective depletion of virus-specific CD8 T cells specifically within liver tissue during chronic lymphocytic choriomeningitis virus infection. Rather than simply blocking the PD-1 inhibitory signal as intended, these therapeutic antibodies actively remove PD-1-expressing T cells through antibody-dependent cellular cytotoxicity mechanisms. The depletion occurred selectively in hepatic tissue while sparing T cells in other organs, suggesting the liver's unique immune microenvironment amplifies this unwanted effect. This represents a fundamental challenge to current understanding of checkpoint inhibitor mechanisms. PD-1 therapy has revolutionized cancer treatment since its clinical introduction, generating billions in revenue while extending survival for patients with melanoma, lung cancer, and other malignancies. However, response rates remain disappointingly low for hepatocellular carcinoma and other liver cancers, with only 15-20% of patients achieving durable responses. The selective hepatic T cell depletion identified here may partially explain these clinical limitations. The implications extend beyond cancer to chronic viral infections like hepatitis B, where PD-1 blockade has shown mixed results. Engineering PD-1 antibodies without functional Fc regions could preserve therapeutic benefit while avoiding counterproductive T cell removal. This represents an incremental but potentially clinically significant refinement to existing immunotherapy approaches rather than a paradigm shift.